This laboratory-developed NGS test protocol is based on a well-validated research use-only kit that targets 54 genes, including all exons of 15 genes (BCOR, BCORL1, CDKN2A, CEBPA, CUX1, DNMT3A, ETV6, EZH2, IKZF1, KDM6A, PHF6, RAD21, RUNX1, STAG2, and ZRSR2) and hot spot exons/regions of 39 genes (ABL1, ASXL1, ATRX, BRAF, CALR, CBL, CBLB, CBLC, CSF3R, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, JAK2, JAK3
, KIT, KMT2A/MLL, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PTEN, PTPN11, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, TET2, TP53, U2AF1, and WT1).
EGFR mutations, anaplastic lymphoma kinase (ALK) fusions, and proto-oncogene tyro sine-protein kinase (ROS1) were detected in non-smokers and smokers, while tumor protein p53 (TP53), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), proto-oncogene B-Raf (BRAF), Janus kinase 2 (JAK2), JAK3
, and mismatch repair gene mutations were detected in smokers.
Blood, under the title, "EZH2 phosphorylation by JAK3
mediates a switch to non-canonical function in natural killer/T-cell lymphoma" by Junli Yan 1, Boheng Li 2, Baohong Lin 3, Pei Tsung Lee 1, Tae-Hoon Chung 1, Joy Tan 1, Chonglei Bi 1, Xue Ting Lee 1, Viknesvaran Selvarajan 4, Siok-Bian Ng 1,2,4, Henry Yang 1, Qiang Yu 5, Wee-Joo Chng 1,2,3